We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Receives Milestone Payment from Boehringer Ingelheim
News

Evotec Receives Milestone Payment from Boehringer Ingelheim

Evotec Receives Milestone Payment from Boehringer Ingelheim
News

Evotec Receives Milestone Payment from Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Receives Milestone Payment from Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.

The milestone was achieved for the identification and selection of a second compound to be advanced into preclinical development within an existing program. This represents the sixth milestone achieved in this multi-year, multi-target collaboration and is the second compound selected for pre-development in the last twelve months.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “It is great to see the scientific progress that top-class discovery alliance projects can bring. We are jointly progressing several projects with Boehringer Ingelheim at this stage, so we are optimistic to see further product progress soon.”
Advertisement